The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.
Pyrogallol is prepared by (A) reacting a halo compound of formula ##STR1## where X represents Br or I, R.sup.1 represents hydrogen, secondary or tertiary alkyl of up to 10 carbon atoms, carboxy or alkoxycarbonyl of 2-5 carbon atoms and R.sup.2 represents hydrogen or alkyl of 1-4 carbon atoms, with an alkali metal alkoxide of formula ROM where M represents an alkali metal and R represents alkyl of 1-4 carbon atoms, to replace each X by OR, and then (B) dealkylating each OR and each OR.sup.2 where R.sup.2 represents alkyl of 1-4 carbon atoms and removing the R.sup.1 group where this is not hydrogen.
METHOD FOR DIMERIZATION OF ETHYLENE COMPRISING A STEP FOR TREATMENT OF THE REACTION EFFLUENT
申请人:IFP Energies Nouvelles
公开号:US20190169085A1
公开(公告)日:2019-06-06
The invention describes a method for dimerization of ethylene implementing a step for treatment of raw effluent by neutralization, at the outlet of the reactor, of the catalyst for dimerization of ethylene into but-1-ene by a particular alcohol.
TRICYCLIC KINASE INHIBITORS OF MELK ANDS METHODS OF USE
申请人:Dana-Farber Cancer Institute, Inc
公开号:US20190084977A1
公开(公告)日:2019-03-21
Provided herein are tricyclic small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a tricyclic compound of the invention and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.
current researches are focused on the use of noble metals as catalyst. In order to give an efficient, benign, activity-adjustable and cost-effective system for halogenation, a series of Ti-Al mixed oxides are prepared as catalyst through sol-gel in this work. Characterizations reveal all catalysts contain more aluminum than titanium, but preparative conditions affect their composition and crystallinity